These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 21060032)

  • 1. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
    Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
    J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
    Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
    J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
    Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
    Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
    J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accumulation of genomic aberrations during clinical progression of medulloblastoma.
    Korshunov A; Benner A; Remke M; Lichter P; von Deimling A; Pfister S
    Acta Neuropathol; 2008 Oct; 116(4):383-90. PubMed ID: 18704466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of medulloblastoma in children under age of three years.
    Ryzhova MV; Zheludkova OG; Kumirova ÉV; Shishkina LV; Panina TN; Gorelyshev SK; Khukhlaeva EA; Mazerkina NA; Matuev KB; Medvedeva OA; Tarasova EM; Kholodov BV; Kapitul'skaia OIu
    Zh Vopr Neirokhir Im N N Burdenko; 2013; 77(1):3-10; discussion 11. PubMed ID: 23659115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2 overexpression is associated with short survival in adults with medulloblastoma.
    Giordana MT; Duó D; Gasverde S; Trevisan E; Boghi A; Morra I; Pradotto L; Mauro A; Chió A
    Neuro Oncol; 2002 Apr; 4(2):115-22. PubMed ID: 11916503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours.
    Goschzik T; Zur Mühlen A; Kristiansen G; Haberler C; Stefanits H; Friedrich C; von Hoff K; Rutkowski S; Pfister SM; Pietsch T
    Neuropathol Appl Neurobiol; 2015 Feb; 41(2):135-44. PubMed ID: 24894640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma.
    Zitterbart K; Filkova H; Tomasikova L; Necesalova E; Zambo I; Kantorova D; Slamova I; Vranova V; Zezulkova D; Pesakova M; Pavelka Z; Veselska R; Kuglik P; Sterba J
    J Neurooncol; 2011 Mar; 102(1):25-33. PubMed ID: 20607354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.
    Park AK; Lee SJ; Phi JH; Wang KC; Kim DG; Cho BK; Haberler C; Fattet S; Dufour C; Puget S; Sainte-Rose C; Bourdeaut F; Grill J; Delattre O; Kim SK; Park WY
    Neuro Oncol; 2012 Feb; 14(2):203-14. PubMed ID: 22090452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
    Waszak SM; Northcott PA; Buchhalter I; Robinson GW; Sutter C; Groebner S; Grund KB; Brugières L; Jones DTW; Pajtler KW; Morrissy AS; Kool M; Sturm D; Chavez L; Ernst A; Brabetz S; Hain M; Zichner T; Segura-Wang M; Weischenfeldt J; Rausch T; Mardin BR; Zhou X; Baciu C; Lawerenz C; Chan JA; Varlet P; Guerrini-Rousseau L; Fults DW; Grajkowska W; Hauser P; Jabado N; Ra YS; Zitterbart K; Shringarpure SS; De La Vega FM; Bustamante CD; Ng HK; Perry A; MacDonald TJ; Hernáiz Driever P; Bendel AE; Bowers DC; McCowage G; Chintagumpala MM; Cohn R; Hassall T; Fleischhack G; Eggen T; Wesenberg F; Feychting M; Lannering B; Schüz J; Johansen C; Andersen TV; Röösli M; Kuehni CE; Grotzer M; Kjaerheim K; Monoranu CM; Archer TC; Duke E; Pomeroy SL; Shelagh R; Frank S; Sumerauer D; Scheurlen W; Ryzhova MV; Milde T; Kratz CP; Samuel D; Zhang J; Solomon DA; Marra M; Eils R; Bartram CR; von Hoff K; Rutkowski S; Ramaswamy V; Gilbertson RJ; Korshunov A; Taylor MD; Lichter P; Malkin D; Gajjar A; Korbel JO; Pfister SM
    Lancet Oncol; 2018 Jun; 19(6):785-798. PubMed ID: 29753700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.
    Zhukova N; Ramaswamy V; Remke M; Martin DC; Castelo-Branco P; Zhang CH; Fraser M; Tse K; Poon R; Shih DJ; Baskin B; Ray PN; Bouffet E; Dirks P; von Bueren AO; Pfaff E; Korshunov A; Jones DT; Northcott PA; Kool M; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognár L; Cho BK; Eberhart CG; Conter CF; Fouladi M; French PJ; Grajkowska WA; Gupta N; Hauser P; Jabado N; Vasiljevic A; Jung S; Kim SK; Klekner A; Kumabe T; Lach B; Leonard JR; Liau LM; Massimi L; Pollack IF; Ra YS; Rubin JB; Van Meir EG; Wang KC; Weiss WA; Zitterbart K; Bristow RG; Alman B; Hawkins CE; Malkin D; Clifford SC; Pfister SM; Taylor MD; Tabori U
    Acta Neuropathol Commun; 2014 Dec; 2():174. PubMed ID: 25539912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
    Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
    J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Episomal amplification of MYCN in a case of medulloblastoma.
    Surace C; Pedeutour F; Trombetta D; Burel-Vandenbos F; Rocchi M; Storlazzi CT
    Virchows Arch; 2008 May; 452(5):491-7. PubMed ID: 18286303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
    Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
    Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of gamma-catenin expression with good prognosis in medulloblastomas.
    Misaki K; Marukawa K; Hayashi Y; Fukusato T; Minamoto T; Hasegawa M; Yamashita J; Fujisawa H
    J Neurosurg; 2005 Mar; 102(2 Suppl):197-206. PubMed ID: 16156230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li-Fraumeni syndrome family.
    Güran S; Tunca Y; Imirzalioğlu N
    Cancer Genet Cytogenet; 1999 Sep; 113(2):145-51. PubMed ID: 10484981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee.
    Ellison DW; Onilude OE; Lindsey JC; Lusher ME; Weston CL; Taylor RE; Pearson AD; Clifford SC;
    J Clin Oncol; 2005 Nov; 23(31):7951-7. PubMed ID: 16258095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation.
    Takei H; Nguyen Y; Mehta V; Chintagumpala M; Dauser RC; Adesina AM
    J Neurosurg Pediatr; 2009 Jan; 3(1):61-5. PubMed ID: 19119907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.